Medpace Holdings Inc (NASDAQ:MEDP) CFO Jesse J. Geiger sold 7,200 shares of Medpace stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $78.03, for a total value of $561,816.00. Following the sale, the chief financial officer now owns 40,948 shares of the company’s stock, valued at $3,195,172.44. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of NASDAQ:MEDP traded down $0.28 during trading on Friday, hitting $70.15. 349,400 shares of the stock were exchanged, compared to its average volume of 484,027. The company has a market capitalization of $2.72 billion, a price-to-earnings ratio of 27.08, a price-to-earnings-growth ratio of 2.07 and a beta of 1.51. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.80 and a current ratio of 0.80. Medpace Holdings Inc has a 1-year low of $47.20 and a 1-year high of $86.71. The company’s fifty day simple moving average is $78.50 and its 200-day simple moving average is $69.43.
Medpace (NASDAQ:MEDP) last announced its earnings results on Tuesday, October 29th. The company reported $0.71 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.71. The company had revenue of $216.20 million for the quarter, compared to analyst estimates of $217.14 million. Medpace had a return on equity of 17.06% and a net margin of 11.35%. The firm’s quarterly revenue was up 20.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.67 earnings per share. On average, research analysts forecast that Medpace Holdings Inc will post 2.92 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in MEDP. Wasatch Advisors Inc. increased its stake in shares of Medpace by 42.8% during the second quarter. Wasatch Advisors Inc. now owns 2,005,127 shares of the company’s stock worth $131,175,000 after purchasing an additional 600,686 shares during the period. APG Asset Management N.V. increased its stake in Medpace by 294.5% during the 2nd quarter. APG Asset Management N.V. now owns 611,413 shares of the company’s stock worth $35,123,000 after acquiring an additional 456,413 shares during the period. BlackRock Inc. increased its stake in Medpace by 9.8% during the 2nd quarter. BlackRock Inc. now owns 4,538,605 shares of the company’s stock worth $296,914,000 after acquiring an additional 406,428 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Medpace by 95.7% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 578,979 shares of the company’s stock worth $37,877,000 after acquiring an additional 283,143 shares during the period. Finally, Invesco Ltd. increased its stake in Medpace by 78.4% during the 2nd quarter. Invesco Ltd. now owns 593,754 shares of the company’s stock worth $38,843,000 after acquiring an additional 260,980 shares during the period. Institutional investors own 83.75% of the company’s stock.
A number of research analysts recently weighed in on the company. SunTrust Banks raised their price objective on Medpace to $85.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Credit Suisse Group lifted their price target on Medpace from $65.00 to $77.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 30th. ValuEngine downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. BidaskClub downgraded Medpace from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Zacks Investment Research downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $77.00.
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
See Also: Arbitrage
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.